The Journal of rheumatology. Supplement最新文献_第7页

Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting. 2021年grappa合作研究网络(CRN)会议纪要。

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.211336

C. Stober, I. McInnes, S. Raychaudhuri, P. Mease, S. Pennington, J. Scher, V. Chandran, A. Armstrong, M. D. de Wit, A. Cauli, D. Jadon, T. Löve, A. Ogdie, D. O'Sullivan, L. V. van Mens, C. Ritchlin, O. FitzGerald

{"title":"Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.","authors":"C. Stober, I. McInnes, S. Raychaudhuri, P. Mease, S. Pennington, J. Scher, V. Chandran, A. Armstrong, M. D. de Wit, A. Cauli, D. Jadon, T. Löve, A. Ogdie, D. O'Sullivan, L. V. van Mens, C. Ritchlin, O. FitzGerald","doi":"10.3899/jrheum.211336","DOIUrl":"https://doi.org/10.3899/jrheum.211336","url":null,"abstract":"At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a number of project updates, including a pilot investigator-initiated study to evaluate liquid and tissue biomarkers associated with axial involvement in psoriatic arthritis (PsA). The GRAPPA-CRN session updated progress made with 3 parallel international research initiatives based on 3 previously defined unmet needs in PsA. The Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES) is a European research consortium formed to address unmet clinical needs in PsA. The Preventing Arthritis in a Multi-Center Psoriasis At-Risk Population (PAMPA) is a US-based organization that has defined consensus terminology for preclinical phases of PsA and is interested in the transition process from psoriasis to PsA. An overview of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program 2.0, a consortium including GRAPPA-CRN members that addressed these 3 unmet needs in PsA, was also presented.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82803619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hide-bound Bowel Sign in Systemic Sclerosis 系统性硬化症的隐藏性肠征

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.210964

A. Hokama

引用次数: 0

Healthcare Utilization and Costs for Musculoskeletal Disorders in Ontario, Canada 加拿大安大略省肌肉骨骼疾病的医疗保健利用和成本

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.210938

J. Power, A. Perruccio, J. Paterson, M. Canizares, C. Veillette, P. Coyte, E. Badley, N. N. Mahomed, Y. R. Rampersaud

{"title":"Healthcare Utilization and Costs for Musculoskeletal Disorders in Ontario, Canada","authors":"J. Power, A. Perruccio, J. Paterson, M. Canizares, C. Veillette, P. Coyte, E. Badley, N. N. Mahomed, Y. R. Rampersaud","doi":"10.3899/jrheum.210938","DOIUrl":"https://doi.org/10.3899/jrheum.210938","url":null,"abstract":"Objective. To examine the magnitude and costs of ambulatory primary care, specialist physician care, and hospital service use for musculoskeletal disorders (MSDs) in Canada’s largest province, Ontario. Methods. Administrative health databases were analyzed for fiscal year 2013–2014 for adults aged ≥ 18 years, including data on physician services, emergency department (ED) visits, and hospitalizations. International Classification of Diseases diagnostic codes were used to identify MSD services. A validated algorithm was used to estimate direct medical costs. Person-visit rates and numbers of persons and visits were tabulated by care setting, age, sex, and physician specialty. Data were examined for all MSDs combined, as well as for specific diagnostic groupings. Results. Overall, 3.1 million adult Ontarians (28.5%) made over 8 million outpatient physician visits associated with MSDs. These included 5.6 million primary care visits. MSDs accounted for 560,000 (12.3%) of all adult ED visits. Total costs for MSD-related care were $1.6 billion, with 12.6% of costs attributed to primary care, 9.2% to specialist care, 8.6% to ED care, 8.5% to day surgery, and 61.2% associated with inpatient hospitalizations. Costs due to arthritis accounted for 40% of total MSD care costs ($639 million). MSD-related imaging costs were $169 million, yielding a total cost estimate of $1.8 billion for MSDs overall. Conclusion. MSDs place a significant and costly burden on the healthcare system. Health system planning needs to consider the large and escalating demand for care to reduce both the individual and population burden.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77338467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Using FibroScan to Assess for the Development of Liver Fibrosis in Patients With Arthritis on Methotrexate: A Single-center Experience 使用纤维扫描评估甲氨蝶呤关节炎患者肝纤维化的发展:单中心经验

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.211281

Saman Darabian, J. Wade, J. Kur, S. Wade, E. C. Sayre, M. Badii

{"title":"Using FibroScan to Assess for the Development of Liver Fibrosis in Patients With Arthritis on Methotrexate: A Single-center Experience","authors":"Saman Darabian, J. Wade, J. Kur, S. Wade, E. C. Sayre, M. Badii","doi":"10.3899/jrheum.211281","DOIUrl":"https://doi.org/10.3899/jrheum.211281","url":null,"abstract":"Objective. Methotrexate (MTX) is often the primary medication to treat various rheumatic diseases (RDs) because of its low cost and its demonstrated efficacy in controlling disease activity. However, a concern has been the potential for hepatic fibrosis associated with long-term MTX usage. This study investigated the association between cumulative MTX intake and development of liver fibrosis by utilizing noninvasive transient elastography (FibroScan). Methods. All patients with inflammatory arthritis treated with MTX were offered screening with FibroScan. A certified technician measured liver stiffness after patients adhered to a fast. Relevant clinical information was obtained by patient survey and medical records review. The population was divided into quartiles based on participants’ cumulative dosage of MTX. Results. Five hundred twenty patients with RD were included in this study. The prevalence of stages F3 or F4 liver fibrosis was 13.3% in the control group and 12.7% in the entire sample. Compared with subgroup 1 (control with cumulative MTX exposure of ≤ 499 mg), MTX subgroups 2 to 4 were not significantly correlated with higher FibroScan scores (P = 0.82, 0.59, and 0.18, respectively). In multivariable linear regression analysis, statistically significant factors for liver stiffness were BMI, waist circumference, male sex, and age. Conclusion. No significant correlation between the cumulative MTX dosage and liver stiffness, even at high MTX doses, was observed. The analyses showed significant correlations between the FibroScan score and BMI. These findings were reassuring in that current rheumatology practice appears to be safe and effective in screening for liver fibrosis in patients on long-term low-dose MTX therapy.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80178390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission 急性痛风的住院治疗:绘制住院过程和确定入院预测因素

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.211203

M. Russell, D. Nagra, Benjamin D. Clarke, Sathiyaa Balachandran, April Buazon, Amy Boalch, K. Bechman, M. Adas, E. Alveyn, A. Rutherford, J. Galloway

{"title":"Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission","authors":"M. Russell, D. Nagra, Benjamin D. Clarke, Sathiyaa Balachandran, April Buazon, Amy Boalch, K. Bechman, M. Adas, E. Alveyn, A. Rutherford, J. Galloway","doi":"10.3899/jrheum.211203","DOIUrl":"https://doi.org/10.3899/jrheum.211203","url":null,"abstract":"Objective. To identify predictors of admission following emergency department (ED) attendances for gout flares and to describe barriers to optimal inpatient gout care. Methods. ED attendances and hospital admissions with primary diagnoses of gout were analyzed at 2 UK-based hospitals between January 1, 2017, and December 31, 2020. Demographic and clinical predictors of ED disposition (admission or discharge) and reattendance for gout flares were identified using logistic regression and survival models, respectively. Case note reviews (n = 59), stakeholder meetings, and process mapping were performed to capture detailed information on gout management and to identify strategies to optimize care. Results. Of 1220 emergency attendances for gout flares, 23.5% required hospitalization (median length of stay: 3.6 days). Recurrent attendances for flares occurred in 10.4% of patients during the study period. In multivariate logistic regression models, significant predictors of admission from ED were older age, overnight ED arrival time, higher serum urate (SU), higher C-reactive protein, and higher total white cell count at presentation. Detailed case note reviews showed that only 22.6% of patients with preexisting gout were receiving urate-lowering therapy (ULT) at presentation. Initial diagnostic uncertainty was common, yet rheumatology input and synovial aspirates were rarely obtained. By 6 months postdischarge, 43.6% were receiving ULT; however, few patients had treat-to-target dose optimization, and only 9.1% achieved SU levels ≤ 360 μmol/L. Conclusion. We identified multiple predictors of hospitalization for acute gout. Treat-to-target optimization of ULT following hospitalization remains inadequate and must be improved if admissions are to be prevented.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77473357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis 类风湿性关节炎男性和女性患者自身抗体的存在:一项系统综述和荟萃分析

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.211020

B. Hadwen, Richard Yu, E. Cairns, Lillian Barra

{"title":"Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis","authors":"B. Hadwen, Richard Yu, E. Cairns, Lillian Barra","doi":"10.3899/jrheum.211020","DOIUrl":"https://doi.org/10.3899/jrheum.211020","url":null,"abstract":"Objective. Rheumatoid arthritis (RA) is more common in females, and although the cause of RA is unknown, it is characterized by the production of autoantibodies. The aims of this study were to determine whether RA-associated autoantibodies are more often found in females than males and to identify factors that influence the relationship between sex and seropositivity. Methods. Databases were searched and studies of RA (N ≥ 100) were included if they reported proportion of seropositive patients with RA by sex. Metaanalyses and metaregression were conducted using the random-effects model. Covariates regressed were smoking, age, BMI, Health Assessment Questionnaire–Disability Index (HAQ-DI), and the Disease Activity Score in 28 joints (DAS28). Results. Eighty-four studies with a total of 141,381 subjects with rheumatoid factor (RF) seropositivity and 95,749 subjects with anticitrullinated protein antibody (ACPA) seropositivity met inclusion criteria. The mean age of participants ranged from 37 to 68 years and the proportion of female subjects ranged from 9% to 92%. Results indicated that females were less likely than males to be seropositive: odds ratio (OR) 0.84 [95% CI 0.77–0.91] for RF and OR 0.88 [95% CI 0.81–0.95] for ACPA. BMI, smoking, mean age, DAS28, and HAQ-DI did not affect the relationship between sex and seropositivity. Conclusion. Although studies report that females have higher RA disease activity than males and that seropositivity predicts worse outcomes, females were less likely to be seropositive than males.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82717574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Increasing Cases of Chronic Nonbacterial Osteomyelitis in Children: A Series of 215 Cases From a Single Tertiary Referral Center 儿童慢性非细菌性骨髓炎病例增加:来自单一三级转诊中心的215例病例

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.210991

Sumaya Aden, Stephen Q. Wong, Claire Yang, T. Bui, Travis Higa, Joshua Scheck, R. Iyer, M. Egbert, A. Lindberg, Yongdong Zhao

{"title":"Increasing Cases of Chronic Nonbacterial Osteomyelitis in Children: A Series of 215 Cases From a Single Tertiary Referral Center","authors":"Sumaya Aden, Stephen Q. Wong, Claire Yang, T. Bui, Travis Higa, Joshua Scheck, R. Iyer, M. Egbert, A. Lindberg, Yongdong Zhao","doi":"10.3899/jrheum.210991","DOIUrl":"https://doi.org/10.3899/jrheum.210991","url":null,"abstract":"Objective Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disease that is gaining recognition from clinicians and researchers. We aim to publish data from our cohort of patients with CNO living in the northwestern United States to increase the awareness of specific demographics, characteristics, and presentation of this rare disease. Methods A retrospective chart review was performed of our electronic medical records. Patients with complete chart records who met criteria for a diagnosis of CNO from 2005 to 2019 were included. Extracted data including patient demographics, bone biopsy results, and lesion locations on advanced imaging were analyzed. King County census data were used to calculate the annual new case rate within our center. Results A total of 215 CNO cases were diagnosed at our large tertiary pediatric hospital. The majority of cases were of White race residing in Washington’s most populous county, King County. Most cases were diagnosed in 2016 to 2019, showing a significant increase in the annual case rate from 8 to 23 per million children in King County, though there did not appear to be a seasonal predilection. Biopsy rate decreased from 75% to 52%. One hundred fifty-two (71%) children had family history of autoimmunity. With increasing use of whole-body magnetic resonance imaging (WB-MRI), results showed 68% had multiple lesions. Conclusion CNO has been diagnosed at an increased rate in recent years. WB-MRI may assist in identifying other lesions that may be asymptomatic on presentation. Bone biopsy is still required in some children at the time of diagnosis.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81346073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

GRAPPA Treatment Recommendations: 2021 Update. GRAPPA治疗建议:2021年更新。

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.211331

L. Coates, N. Corp, D. A. van der Windt, D. O'Sullivan, E. Soriano, A. Kavanaugh

引用次数: 16

Axial Spondyloarthritis in Diffuse Idiopathic Skeletal Hyperostosis 弥漫性特发性骨骼增生引起的轴性脊椎关节炎

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.220082

K. Aso, M. Kato, T. Atsumi

引用次数: 0

Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study 成纤维细胞生长因子23水平与系统性硬化症相关的肺受累:一项概念验证研究

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI: 10.3899/jrheum.211156

L. Amezcua-Guerra, M. Mora-Ramírez, G. Vancini, V. Jiménez-Rojas, R. Márquez-Velasco

引用次数: 0